X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Pharmacology Research & Perspectives

期刊標題檢索 PHARMACOL RES P 最新評論: Painfully, it has been under review for 4 months. (2023-03-03)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Pharmacology Research & Perspectives]您好,您是該頁面的第 17138 位訪客。

期刊簡介
期刊名稱Pharmacology Research & Perspectives Pharmacology Research & Perspectives
LetPub Score
4.9
50 ratings
Rate

Reputation
5.9

Influence
3.6

Speed
6.9

期刊簡稱PHARMACOL RES PERSPE
ISSN2052-1707
h-indexN.A.
CiteScore
CiteScoreSJRSNIPCiteScore Rank
5.300.7900.786
Subject fieldQuartilesRankPercentile
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: General Pharmacology, Toxicology and Pharmaceutics
Q111 / 80
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Neurology
Q270 / 192

自引率 (2023-2024)0.00%自引率趨勢
掲載範囲
PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS
官方網站http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2052-1707
在線稿件提交
開放訪問Yes
出版商Wiley-Blackwell
主題領域Pharmacology, Toxicology and Pharmaceutics
出版國/地區ENGLAND
發行頻率
創刊年0
每年文章數104每年文章數趨勢
黃金OA百分比67.87%
OA Related Info
APC: Yes( USD3850; GBP2420; EUR2810; )
APC waiver:Check Notes
Other charges: No
Keywords: perspectives、pharmacology、replication studies、target validation
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardPeer review
Web of Science 四分位
2023-2024
WOS Quartile: Q2

CategoryEditionJIF QuartileJIF RankingJIF Percentage
PHARMACOLOGY & PHARMACYSCIEQ2147/354
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2052-1707%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 20 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Pharmacology Research & Perspectives】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Acta Pharmaceutica Sinica BH-index: 28

    CiteScore: 22.40
    Antibiotics-BaselH-index: 0

    CiteScore: 7.30
    Therapeutics and Clinical Risk ManagementH-index: 0

    CiteScore: 5.30
    Revista Brasileira de Farmacognosia-Brazilian Journal of PharmacognosyH-index: 37

    CiteScore: 2.60
    Infarma Pharmaceutical SciencesH-index: 0

    CiteScore: 0.10
    Mental Health ClinicianH-index: 0

    CiteScore: 1.90
    Pharmacological Research Modern Chinese MedicineH-index: 0

    CiteScore: 1.60
    學科內最受檢索的期刊 頁面查看次數
    Acta Pharmaceutica Sinica B202581
    Antibiotics-Basel33465
    Revista Brasileira de Farmacognosia-Brazilian Journal of Pharmacognosy15828
    Therapeutics and Clinical Risk Management5963
    Infarma Pharmaceutical Sciences1581
    Pharmacological Research Modern Chinese Medicine1298
    Mental Health Clinician418
  •  

    Pharmacology Research & Perspectives Pharmacology Research & Perspectives
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [Pharmacology Research & Perspectives] 的評論撰寫評論
作者: thisone


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-03-03 22:44:50 評論於
Painfully, it has been under review for 4 months.
(0) 讚! | thisone

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [Pharmacology Research & Perspectives] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*